ad image

Q12022

1 / 2
Samsung Biologics
Financial Results

Samsung Biologics Reports First Quarter 2022 Financial Results

Samsung Biologics

PR-M04-22-14Apr 27, 2022
Advancing Visual Inspection of Printed Pharmaceutical Materials
Automated Visual Inspection

Advancing Visual Inspection of Printed Pharmaceutical Materials

Florian Krickl; Stephen Makepeace-Warne

PAO-03-022-CL-24Mar 28, 2022
Alzheimer Drug Still Controversial
Column: New Drug Watch

Alzheimer Drug Still Controversial

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-022-NI-04Mar 23, 2022
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Column: Technology

mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez

Pharma's Almanac

PAO-03-022-NI-02Mar 23, 2022
HEK Cells vs. CHO Cells in Recombinant Antibody Production: What's the Better Choice
Recombinant Antibody Production

HEK Cells vs. CHO Cells in Recombinant Antibody Production: What's the Better Choice

evitria AG

PAO-03-022-CL-22Mar 22, 2022
Unique Vector Expression Technologies for Boosting Protein Production in E. coli
Biomanufacturing

Unique Vector Expression Technologies for Boosting Protein Production in E. coli

Trond Erik Vee Aune, Ph.D.

Vectron Biosolutions

PAO-02-022-CL-16Mar 20, 2022
Changing the Future of Cell Culture and Accelerating Next-Generation Therapies
Cell Culture

Changing the Future of Cell Culture and Accelerating Next-Generation Therapies

A.J. Mellott, Ph.D.; Scott Leigh

Ronawk

PAO-02-022-CL-20Mar 20, 2022
Overcoming Analytical Challenges for Gene Therapies
Gene Therapy Analytics

Overcoming Analytical Challenges for Gene Therapies

Jennifer Chadwick, Ph.D.

ProtaGene

PAO-02-022-CL-14Mar 20, 2022
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
COVID-19 Vaccines

Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-022-NI-05Mar 18, 2022
Will Remote Pharma GMP Auditing Continue Post-COVID?
Remote Auditing

Will Remote Pharma GMP Auditing Continue Post-COVID?

Alasdair Leckie

PAO-02-022-CL-21Mar 16, 2022
Streamlining Process Validation for Drug Substance Manufacturing
Process Validation

Streamlining Process Validation for Drug Substance Manufacturing

Gerhard Noessner, Ph.D.; Juergen Utz, Ph.D.; Juergen Bank, Ph.D.

Fareva

PAO-02-022-CL-19Mar 15, 2022
Sterile Injectables Device and Packaging Trends
Sterile

Sterile Injectables Device and Packaging Trends

James Grote

Nice Insight

PAO-02-022-NI-01Mar 14, 2022
The Limitless Potential of Thin Film Freezing
Solubility

The Limitless Potential of Thin Film Freezing

Glenn Mattes

TFF Pharmaceuticals, Inc.

PAO-01-22-CL-04Mar 12, 2022
Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases
Neurodegenerative Diseases

Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases

Rob Etherington

PAO-01-22-CL-06Mar 12, 2022
Developing New Antibody Therapeutics for COVID-19 and Beyond
Antibody Therapeutics

Developing New Antibody Therapeutics for COVID-19 and Beyond

Ian Chan

Abpro

PAO-01-22-CL-01Mar 12, 2022
Rare Disease Patients Benefit from Clinical Trial Flexibility
Rare Disease Clinical Trials

Rare Disease Patients Benefit from Clinical Trial Flexibility

Tim Rich; Meredith McCumbee; Francis Jones, Ph.D.

PPD, part of Thermo Fisher Scientific

PAO-02-022-CL-03Mar 12, 2022
Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations
Excipients

Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations

Tobias Rosenkranz, Ph.D.; Sara Kalman

MilliporeSigma

PAO-01-22-CL-02Mar 12, 2022
Changing the Paradigm of Cancer Drug Discovery and Development with Plants
Oncology

Changing the Paradigm of Cancer Drug Discovery and Development with Plants

Martin Brenner, DVM, Ph.D.; Randy Maddux; Steven King

iBio, Inc.

PAO-02-022-CL-02Mar 12, 2022
Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing
Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

Andrew Moreo; Lenore Giannunzio

Andelyn Biosciences

PAO-02-022-CL-01Mar 12, 2022
The Global Immunization Disparity
COVID-19 Vaccines

The Global Immunization Disparity

Komal Hatti

IPS-Integrated Project Services, LLC

PAO-02-022-CL-04Mar 12, 2022
1 / 2